The core activity of PDC Therapeutics is the development of targeted polymer-drug conjugate technologies and smart nanomedicines for targeted therapies, particularly using the proprietary Sagitta biodegradation platform, to offer patients an optimal therapeutic ratio.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Targeted chemotherapy programmes for solid tumours, including RS-0139, RS-0337, RS-0461, RS-0625 and RS-0735 in preclinical and clinical development.
Radioligand Diagnostic / Therapy
Radioligand diagnostic and therapeutic programmes for solid tumours and HER2+ tumours, including theranostic pairs RS-0826 and RS-0964 and therapeutic candidate RS-1047.
Sagitta® biodegradable conjugation platforms
Sagitta® biodegradable conjugation platforms for smart nanomedicines, designed to improve therapeutic index, pharmacokinetics, specificity and manufacturability.
Polymer-Drug Conjugate technology
Targeted Polymer-Drug Conjugate technologies for developing smart nanomedicines and therapies with an optimal therapeutic index.
Knowledge
No knowledge articles yet
Once PDC Therapeutics SA has claimed this profile, we'll publish editorial articles and case studies here together.